Pain-free at two hours is when the trial stops counting.
Migraine drug trials stop counting at 120 minutes. Your recovery doesn't. Here's how to judge whether a treatment works using the whole attack.
Two hours in, the diary says it worked
The timer on your phone says 2:04. The throbbing behind your left eye is gone. You open your tracker, tap "pain: none," and by the standard migraine drug trials use, the medication just worked.
Then comes the rest of the day. Screen brightness still lands like a punch. You reread the same email three times. Your neck is stiff, and the fatigue has that particular weight sleep doesn't fix. Tomorrow morning you're better, mostly. Tomorrow afternoon, finally, you're back.
None of those hours show up in the entry that said the drug worked.
And that entry is what you'll describe to your neurologist at your next appointment.
The Two Clocks problem
Every treated migraine attack runs on two clocks.
The trial clock starts when you take the dose and stops at 120 minutes, when researchers ask one question: is the pain gone? The recovery clock starts at the same moment and stops when you can work, drive, parent, and think the way you did before the attack began.
Clinical research built its definition of success on the first clock. Patients live on the second. So when a neurologist asks "is this medication working for you?" you're usually answering on the trial clock without noticing a second one exists.
Those clocks can disagree by a day or more. A two-hour entry can't tell you which treatment shortens the whole attack and which one only shortens the headache.
The trial clock stops at 120 minutes. Yours stops when you're back.
Why the two-hour endpoint exists, and where it stops being useful
The two-hour endpoint has good reasons behind it. Trials need an outcome that's measurable, comparable across studies, and able to separate a drug from placebo. Pain freedom at two hours does that cleanly. The International Headache Society's guidelines for controlled trials of acute migraine treatment recommend it as the primary efficacy measure, and the FDA's 2018 guidance on developing acute migraine drugs pairs it with freedom from the most bothersome symptom, also measured at two hours.
For approving a drug, that design makes sense. For deciding whether a drug fits your life, it's incomplete. A label describes how a study population's pain behaved inside a fixed window. It can't describe how long your fog, residual photophobia, or exhaustion lasted after the pain resolved, because the trial never asked.
Even the longer endpoints stay on the pain axis. Sustained pain freedom from 2 to 24 hours and from 2 to 48 hours are standard secondary measures, and they're designed to catch the headache coming back. Being unable to function while the headache stays gone falls outside all of them.
What drug labels measure vs. what postdrome research measures
Pull up the prescribing information for the gepants approved for acute treatment, ubrogepant (Ubrelvy) and rimegepant (Nurtec ODT), and the pivotal trials rest on the same two-hour co-primary structure. Triptan labels lean on two-hour headache response or relief. Nurtec ODT Section 14 primary endpoints were headache pain freedom and MBS freedom at two hours post-dose vs. placebo ([source](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf))
The postdrome literature measures a different stretch of the attack entirely. Prospective diary research, including the study at PMC6347475, reports non-headache symptoms persisting after pain resolution in According to Bose & Goadsby (2016), 81% of migraineurs experience a postdrome phase after headache resolves, lasting on average about 25 hours and ranging from a few hours up to three days., lasting Postdrome (the after-migraine phase Postdrome is named for) typically lasts several hours up to about 3 days, averaging roughly one full day (around 25 hours) per episode.. Tiredness, trouble concentrating, and neck stiffness are among the most commonly reported. Postdrome cites peer-reviewed migraine research (Bose & Goadsby, Neurology 2016; Giffin 2016) identifying fatigue, cognitive impairment (brain fog), residual light sensitivity, and mood changes as the dominant postdrome symptom cluster, and the app's own postdrome-phase analytics track and surface exactly this cluster (plus sound sensitivity, nausea, and dizziness) from users' logged events.
Set those side by side and the gap is structural. The measurement that defines a successful treatment closes before the phase that often decides whether you get the rest of your day back.
Measure
When it's assessed
What it captures
Covers postdrome?
Pain freedom
2 hours after dose
Headache gone
No
Most bothersome symptom freedom
2 hours after dose
Your chosen worst symptom (nausea, photophobia, or phonophobia) gone
No
Sustained pain freedom
2 to 24 hours, 2 to 48 hours
Headache gone and stays gone
No
Return to baseline (not a standard trial endpoint)
Sources: IHS guidelines for controlled trials of acute migraine treatment (Diener et al., Cephalalgia) Postdrome grounds its clinical thresholds (chronic migraine, medication-overuse headache, migraine feature criteria) in the ICHD-3, the third edition of the International Classification of Headache Disorders; the repo does not separately state ICHD-3's publication year.; FDA Guidance for Industry, Migraine: Developing Drugs for Acute Treatment (2018). The last row is the patient-tracked measure this article recommends.
Two attacks a pain diary scores the same
Picture a hypothetical patient comparing two acute medications over a few months. Here's how one attack on each looks.
Attack one: dose at 9 a.m., pain-free by 11. The light sensitivity and fog lift by mid-afternoon. They're cooking dinner at 6.
Attack two: the other drug, dose at 9 a.m., pain-free by 10:40. Faster, on paper. But the fog holds through the evening, the neck stiffness is still there at bedtime, and they start work late the next morning because they can't hold a thought together.
A two-hour diary logs both as successes, with the second looking slightly better. A diary that runs to baseline shows attack two cost close to an extra day. If that repeats, the "faster" drug is the worse fit for this person, and nobody finds out unless the log kept going after the pain stopped.
Two attacks prove nothing on their own. Postdrome length varies from attack to attack for reasons unrelated to the medication. That's exactly why this tracking has to run across many attacks.
How do I know if my migraine medication is working?
Track to baseline, then report it that way. For each treated attack, log four things:
When you took the medication.
2. When the pain was gone.
3. When you were back to baseline: fog, fatigue, light sensitivity, and stiffness cleared enough to function normally.
4. What you couldn't do in between.
The gap between line 2 and line 3 is the number your neurologist rarely gets. Over a few months it answers the real question: does this treatment shorten the whole attack, or only the headache?
Then change how you describe it. "It usually knocks the pain out" gives a clinician almost nothing. "Pain's gone in about two hours, but on most attacks I'm not functional until the next afternoon" gives them something to act on, whether that's a different acute option, a preventive conversation, or a closer look at the recovery phase itself.
Use this data with your clinician
Postdrome tracking is for the conversation with your doctor. Don't stop or switch a medication on your own based on it. And a lingering symptom that's new, severe, or unlike your usual pattern (weakness, numbness, speech changes, confusion, or a sudden worst-ever headache) needs prompt medical care, not a tracker entry.
A timeline that keeps running after the headache ends
Most migraine trackers are shaped around the headache: a start time, an end time, a pain score. That shape quietly bakes the trial clock into your records. When the pain entry closes, the attack closes with it.
Postdrome is built on the other clock. The timeline keeps going through the after-phase, so brain fog, residual photophobia, fatigue, and neck stiffness get logged as part of the same attack instead of vanishing. Aura mode keeps logging possible when a bright screen is the last thing you can face. Your data stays on your device, and you can export it, because the point of a full-attack history is putting it in front of the person prescribing your treatment.
What we're watching
We're watching whether acute-treatment trials start reporting return to normal function past the 24-hour mark, and whether postdrome symptoms ever show up as a named secondary endpoint. Until they do, the only full-attack efficacy data for your treatment is the data you keep.
Log to baseline. Not to pain-free.
Track your next attack all the way to baseline with Postdrome.
Acute migraine trials judge treatments at the two-hour mark, and most trackers mirror that by closing an attack when the pain stops. Postdrome keeps the timeline open through the after-phase, logs fog, residual photophobia, fatigue, and neck stiffness as part of the same attack, stores everything on your device, and exports a full-attack history you can hand to your neurologist.
